9

:
, , ?
. MD,M.Sc.Ph.D (c)
/
...
28/2 -2/3/2014

o
o:

o o
o
o o
&
o

o o
o.

Available at http://static.diavgeia.gov.gr/doc/45-2

100%
..

( )

,
,
:

/
/ (
)

 ()

(!!!)

(!)

C ( , )

:
:

 (xNz)

: ,

1, 2, 3, 4, 5, 6, 7, 8
1, 2, 3, N4, 5, 6, N7,
8, N9, 10, 11, 12, 13,
14, 15, 16

11, 32

 20 .

1918: Spanish Flu

1957: Asian Flu

1 .

20-40 .

1920

1940

1968: Hong Kong Flu

1 .

1960

1980

2000


(11) v

10 15%

(11)v

 &
:
: 4
-

: (, ,
)

(.. , )

1
7

 & C
:

C:

...

2013-2014 :

- A/California/7/2009 (H1N1) pdm09

- A/Victoria/361/2011 (H3N2)
- B/Wisconsin/1/2010

60
2 3


, ,

,

>40

, ,
,

,
<6

,
,

-
<9
,
4

 : /

Guillain-Barre
,
, ,

:
,

: ,
, , ,
: , ,
, ,
,

(70-90%)
2-3
6-12

- 4




6 3

: Vaxigrip, Influvac,
Agrippal,Fluarix

50
. 1

Streptococcus
pneumoniae



. 6-8

1. Centers for Disease Control and Prevention. MMWR. Prevention of Pneumococcal Disease. ACIP Recommendations 1997;46:RR8. 2. Austrian R et al. Ann Intern Med.
1964;60:759-776. 3. Fine MJ et al. JAMA. 1996;274:134-141. 4. Feikin DR et al. Am J Pub Health. 2000;90:223-229. 5. Restrepo MI et al. Chest. 2008;133:610-617.
6. ECDC report. Antimicrobial resistance surveillance in Europe 2010. 7. Liares J et al. Clin Microbiol Infect. 2010;16:402-410. 8 Kyaw MH et al. N Engl J Med.
2006;354:1455-1463.

 :
1

(WHO 2002)

2.000.000

1.500.000

All Ages
Children <5 yrs

1.000.000

500.000
Polio,
diphtheria,
yellow fever

0
Pneumococcal
disease

Measles

Rotavirus

Hib

Pertussis

Tetanus

World Health Organization. Global immunization data; January 2008.

http://www.who.int/immunization/newsroo /Global_Immunization_Data.pdf. Accessed April 26, 2009.

Other

Meningococcus

(, 2009)

45

35
5

30
25

20

15
2
10
1

5
0

0
<1

2-4

5-17
()

18-34

35-49

50-64

50-64

1. Centers for Disease Control and Prevention. 2010. Active Bacterial Core Surveillance Report, Emerging Infections Program Network,
Streptococcus pneumoniae, 2009.

65

65

( 100.000)

( 100.000)

40

 ()

1,2

()

()

*
**
1. WHO. Acute Respiratory Infections (Update September 2009). 2. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine Preventable
Diseases. The Pink Book. 11th Edition. May 2009.

 ,

1a

Calgary, Alberta Canada . 1998-2007

100
90
80
70
60
Meningitis
Pneumonia
Bacteraemia only

50
40
30
20
10
0
0-5
6-23
months months

2-4
years

5-15
years

16-64
years

65-84
years

85
years

Total

N= 1182 .

, 6% , 75% 17% 1a
1. Kellner JD, CID, 2009

SE1005,23-5-11

CO00655

 1
, 21/11/2011

http://static.diavgeia.gov.gr/doc/45-2

http://static.diavgeia.gov.gr/doc/45-2

23-
PNEUMO 23, PNEUMOVAX

23
1,2,3,4,5,6B,7F,8,9N,9V,10A,11A,12F,14,15B,17F,18C,19A,19F,20,22F,23F,33
25 g .

~90 % ,
2-3 2

&

: 6 :76.1%, 12
: 91.7%.
50-70%.

1,3,4,8,9V,14 .

: (,
, , , ), 38.8C.
Pneumovax : <3
.

0.5 mL Pneumo 23
(0.5 mL) Pneumovax

SPMSD, SmPC PNEUMO 23, 2010

SPMD, SmPc PNEUMOVAX, 2010

CO00655

 PPV23
5 1a,b,c, 2b
PPV23 120 ( 60 f
, 71 : 65-88 ).
4,14,23F.
GMTs 95%CI (OPK) * 65
23F.
2.

IgG

* .

1. Musher DM et al, J Infect Dis,2010; 2. Manoff S et al, J Infect Dis, 2010

1000 50 years


PPV23 1a,2g
(, )

30-50%
< 48
,
.

( Arthus)
388C

:
3

1.Hammitt LL, Vaccine, 2011 ; 2. Musher DM, J Infect Dis, 2010; 3. CDC, in Pink Book, 2008; 4. WHO, position paper,2008; 5. Jackson LA, Jama,1999;
6. SmPC Pneumovax II, 2009, 7. SmPC Pneumo 23,2010.

CO00655

 Prevenar 13 13
S.pneumoniae

Prevenar 13

50-76% ( )
50+ 1
1. Prevenar 13 Summary of Product Characteristics, Dec 2011


, 24/10/2011

Streptococcus pneumoniae, > 50
.

( ):

,

Streptococcus pneumoniae ,
6 17

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Summary_for_the_public/human/001104/WC500057248.pdf


, 09/07/2013

Streptococcus pneumoniae, 18 .

( ):

,

Streptococcus pneumoniae ,
6 17

http://ec.europa.eu/health/documents/community-register/2013/20130709126228/anx_126228_el.pdf

 ;1

(ps) () 1
1. Pollard AJ et al. Nat Rev Immunol. 2009;9:213-220.

 ;1,2

B
T

T-

T-

,
1,2

1. de Roux A et al. Clin Infect Dis. 2008;46(7):1015-23. 2. Pollard AJ et al. Nat Rev Immunol. 2009;9:213-220.

 50

1 *

PPV

PPV

Prevenar 13 .

* Prevenar 13 .1

, 23 , Prevenar 13 1

1. Prevenar 13 Summary of Product Characteristics, Dec 2011

European Respiratory Society and the European Lung Foundation. Lung Health in Europe: Facts & Figures: a better understanding of
lung disease and respiratory care in Europe. 2003:1-60. http://www.european lungfoundation.org/uploads/Document/
WEB_CHEMIN_13411_122285371.pdf. Accessed February 18, 2010.

10


.

10

()

37.163

156.006

133.281

119.334.821,7
397.129.180,7
313.663.094,3
830.127.096,7

,
0,83 . 10 83 .
. * +
Athanasakis et. al 2013

( )


: ,

,

: 6,8%
: 7,1% (Minas et al 2010)

, ,

(
/)

=

+

(Athanasakis et al 2010)
: 981,72
:1566,12
59,5%
(584,42)

660.000
, 45%,
173,5

,

.

(, , .)

(costeffective) *Bloom 2005]